OTCMKTS:VNLPY - Vernalis Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.38
+0.30 (1.20%)
Get New Vernalis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VNLPY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VNLPY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Vernalis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.38.
N/A
The current consensus among 0 investment analysts is to n/a stock in Vernalis. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
6/25/2016Stifel NicolausReiterated RatingBuy
i
(Data available from 4/14/2016 forward)
Vernalis logo
Vernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It is also has licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. In addition, the company is developing V158866, a fatty acid amide hydrolase inhibitor for the treatment of pain; CPI-444, an adenosine A2A receptor antagonist, which is in Phase I/Ib clinical trial to treat patients with various solid tumors; and AUY922, an intravenous Hsp90 inhibitor for treating cancer, as well as CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukemia and myelodysplastic syndrome under Phase II trial. Further, it is developing S55746, a selective Bcl-2 inhibitor that is in Phase I study for the treatment of cancer; V158411 molecule; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc.; Biogen Idec; Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc.; Novartis Pharma AG; Servier Research Group; GlaxoSmithKline plc; Genentech; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.
Read More

Today's Range

Now: $0.38
$0.38
$0.38

50 Day Range

MA: N/A

52 Week Range

Now: $0.38
$0.05
$0.58

Volume

N/A

Average Volume

N/A

Market Capitalization

$100.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Vernalis?

The following Wall Street analysts have issued research reports on Vernalis in the last year:
View the latest analyst ratings for VNLPY.

What is the current price target for Vernalis?

0 Wall Street analysts have set twelve-month price targets for Vernalis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Vernalis in the next year.
View the latest price targets for VNLPY.

What is the current consensus analyst rating for Vernalis?

Vernalis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VNLPY.

What other companies compete with Vernalis?

How do I contact Vernalis' investor relations team?

Vernalis' physical mailing address is 100 BERKSHIRE PLACE WHARFEDALE ROAD, WINNERSH X0, RG41 5RD. The company's listed phone number is 44-11-8938-0000. The official website for Vernalis is www.vernalis.com.